Sanofi

Our Pipeline

Updated on July 30, 2026.

Our determination to find answers for patients and their families motivates us to pursue medicines and vaccines with the greatest potential to improve lives and protect public health. With a strong focus on difficult-to-treat diseases and immunization, our R&D pipeline includes 61 clinical-stage projects, 24 of which are in phase 3 or have been submitted to regulatory authorities for approval. Some of these are new molecular entities while others are existing products with potential new indications, or different formulations. All of them are made possible by people who volunteer to participate in a clinical trial.

Phase 1
16
Phase 2
21
Phase 3
20
Registration
4

Changes that occurred in our R&D pipeline are detailed in our quarterly earnings press release, issued on July 30, 2026.

Search for a Specific Clinical-Stage Project

All therapeutic areas
All phases
All expected timeline
61 project(s) of 61
Therapeutic Area
Phase
Name
Description
Indication

Therapeutic Area

Immunology

1
2
3
R

Name

SAR446422

Phase

1
2
3
R

Description

CD28xOX40 bispecific Ab

Indication

Inflammatory indication

Inflammatory indication

Therapeutic Area

Immunology

1
2
3
R

Name

SAR447971

Phase

1
2
3
R

Description

IRAK4 degrader
New

Indication

Hidradenitis suppurativa

New

Hidradenitis suppurativa

New

Therapeutic Area

Immunology

1
2
3
R

Name

SAR448501

Phase

1
2
3
R

Description

CD20 bispecific mAb

Indication

Inflammatory indication

Inflammatory indication

Therapeutic Area

Immunology

1
2
3
R

Name

brivekimig

Phase

1
2
3
R

Description

TNFaxOX40L Nanobody® VHH

Indication

Type 1 diabetes, stage 3

Type 1 diabetes, stage 3

Therapeutic Area

Immunology

1
2
3
R

Name

brivekimig

Phase

1
2
3
R

Description

TNFaxOX40L Nanobody® VHH

Indication

Crohn’s disease

Crohn’s disease

Therapeutic Area

Immunology

1
2
3
R

Name

brivekimig

Phase

1
2
3
R

Description

TNFaxOX40L Nanobody® VHH

Indication

Ulcerative colitis

Ulcerative colitis

Therapeutic Area

Immunology

1
2
3
R

Name

brivekimig

Phase

1
2
3
R

Description

TNFaxOX40L Nanobody® VHH

Indication

Hidradenitis suppurativa

Hidradenitis suppurativa

Therapeutic Area

Immunology

1
2
3
R

Name

frexalimab

Phase

1
2
3
R

Description

CD40L mAb

Indication

Type 1 diabetes, stage 3

Type 1 diabetes, stage 3

Therapeutic Area

Immunology

1
2
3
R

Name

lunsekimig

Phase

1
2
3
R

Description

IL13xTSLP Nanobody® VHH

Indication

Asthma, high-risk

Asthma, high-risk

Therapeutic Area

Immunology

1
2
3
R

Name

lunsekimig

Phase

1
2
3
R

Description

IL13xTSLP Nanobody® VHH

Indication

Chronic rhinosinusitis with nasal polyps

Chronic rhinosinusitis with nasal polyps

Therapeutic Area

Immunology

1
2
3
R

Name

lunsekimig

Phase

1
2
3
R

Description

IL13xTSLP Nanobody® VHH

Indication

Asthma

Asthma

Therapeutic Area

Immunology

1
2
3
R

Name

SAR444336

Phase

1
2
3
R

Description

Non-beta IL2 Synthorin™

Indication

Microscopic colitis

Microscopic colitis

Therapeutic Area

Immunology

1
2
3
R

Name

SAR445399

Phase

1
2
3
R

Description

IL1R3 mAb

Indication

Hidradenitis suppurativa

Hidradenitis suppurativa

Therapeutic Area

Immunology

1
2
3
R

Name

SAR449028

Phase

1
2
3
R

Description

Wild-type KIT inhibitor

Indication

Chronic urticaria

Chronic urticaria

Therapeutic Area

Immunology

1
2
3
R

Name

Dupixent

Phase

1
2
3
R

Description

IL4R mAb

Indication

Chronic pruritis of unknown origin

Chronic pruritis of unknown origin

Therapeutic Area

Immunology

1
2
3
R

Name

duvakitug

Phase

1
2
3
R

Description

TL1A mAb

Indication

Crohn's disease

Crohn's disease

Therapeutic Area

Immunology

1
2
3
R

Name

duvakitug

Phase

1
2
3
R

Description

TL1A mAb

Indication

Ulcerative colitis

Ulcerative colitis

Therapeutic Area

Immunology

1
2
3
R

Name

frexalimab

Phase

1
2
3
R

Description

CD40L mAb

Indication

Kidney transplant rejection

Kidney transplant rejection

Therapeutic Area

Immunology

1
2
3
R

Name

lunsekimig

Phase

1
2
3
R

Description

IL13xTSLP Nanobody® VHH

Indication

Chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease

Therapeutic Area

Immunology

1
2
3
R

Name

Rezurock

Phase

1
2
3
R

Description

ROCK2 inhibitor

Indication

Chronic lung allograft dysfunction

Chronic lung allograft dysfunction

Therapeutic Area

Neurology

1
2
3
R

Name

SAR446597

Phase

1
2
3
R

Description

BbxC1s AAV gene therapy

Indication

Geographic atrophy in dry age-related macular degeneration

Geographic atrophy in dry age-related macular degeneration

Therapeutic Area

Neurology

1
2
3
R

Name

SAR448851

Phase

1
2
3
R

Description

TREM2 agonist

Indication

Alzheimer’s disease

Alzheimer’s disease

Therapeutic Area

Neurology

1
2
3
R

Name

SAR402663

Phase

1
2
3
R

Description

sFLT01 AAV gene therapy

Indication

Wet age-related macular degeneration

Wet age-related macular degeneration

Therapeutic Area

Neurology

1
2
3
R

Name

frexalimab

Phase

1
2
3
R

Description

CD40L mAb

Indication

Relapsing multiple sclerosis

Relapsing multiple sclerosis

Therapeutic Area

Neurology

1
2
3
R

Name

frexalimab

Phase

1
2
3
R

Description

CD40L mAb

Indication

Non-relapsing secondary progressive MS

Non-relapsing secondary progressive MS

Therapeutic Area

Neurology

1
2
3
R

Name

riliprubart

Phase

1
2
3
R

Description

C1s mAb

Indication

IVIg-treated CIDP

IVIg-treated CIDP

Therapeutic Area

Oncology

1
2
3
R

Name

SAR445953

Phase

1
2
3
R

Description

CEACAM5-Topo1 ADC

Indication

Colorectal cancer

Colorectal cancer

Therapeutic Area

Oncology

1
2
3
R

Name

SAR446523

Phase

1
2
3
R

Description

GPRC5D mAb

Indication

Relapsed/refractory multiple myeloma

Relapsed/refractory multiple myeloma

Therapeutic Area

Oncology

1
2
3
R

Name

SAR449336

Phase

1
2
3
R

Description

Pan KRAS inhibitor
New

Indication

Colorectal cancer

New

Colorectal cancer

New

Therapeutic Area

Oncology

1
2
3
R

Name

SAR445877

Phase

1
2
3
R

Description

PD1xIL15 fusion protein

Indication

Solid tumors

Solid tumors

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa

Phase

1
2
3
R

Description

CD38 mAb

Indication

Relapsed/refractory multiple myeloma in combination

Relapsed/refractory multiple myeloma in combination

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa

Phase

1
2
3
R

Description

CD38 mAb

Indication

NDMM, TE (IsKia)

NDMM, TE (IsKia)

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa

Phase

1
2
3
R

Description

CD38 mAb

Indication

NDMM, TE (HD7)

NDMM, TE (HD7)

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa

Phase

1
2
3
R

Description

CD38 mAb

Indication

Smoldering multiple myeloma (ITHACA)

Smoldering multiple myeloma (ITHACA)

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa

Phase

1
2
3
R

Description

CD38 mAb subcutaneous

Indication

Multiple myeloma (CN)

Multiple myeloma (CN)

Therapeutic Area

Rare Diseases

1
2
3
R

Name

SAR446268

Phase

1
2
3
R

Description

DMPK AAV gene therapy

Indication

Myotonic dystrophy type 1

Myotonic dystrophy type 1

Therapeutic Area

Rare Diseases

1
2
3
R

Name

efdoralprin alfa

Phase

1
2
3
R

Description

AAT fusion protein

Indication

Alpha-1 antitrypsin deficiency emphysema

Alpha-1 antitrypsin deficiency emphysema

Therapeutic Area

Rare Diseases

1
2
3
R

Name

frexalimab, rilzabrutinib, brivekimig

Phase

1
2
3
R

Description

CD40L mAb, BTK inhibitor, TNFaxOX40L Nanobody® VHH

Indication

Focal segmental glomerulosclerosis / minimal change disease

Focal segmental glomerulosclerosis / minimal change disease

Therapeutic Area

Rare Diseases

1
2
3
R

Name

Wayrilz

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Graves' disease

Graves' disease

Therapeutic Area

Rare Diseases

1
2
3
R

Name

elenestinib

Phase

1
2
3
R

Description

D816V-mutated KIT inhibitor

Indication

Indolent/smoldering systemic mastocytosis

Indolent/smoldering systemic mastocytosis

Therapeutic Area

Rare Diseases

1
2
3
R

Name

fitusiran

Phase

1
2
3
R

Description

RNAi targeting antithrombin

Indication

Hemophilia A and B (EU, JP)

Hemophilia A and B (EU, JP)

Therapeutic Area

Rare Diseases

1
2
3
R

Name

Nexviazyme

Phase

1
2
3
R

Description

Enzyme replacement therapy

Indication

Infantile-onset Pompe disease (US)

Infantile-onset Pompe disease (US)

Therapeutic Area

Rare Diseases

1
2
3
R

Name

Wayrilz

Phase

1
2
3
R

Description

BTK inhibitor

Indication

IgG4-related disease

IgG4-related disease

Therapeutic Area

Rare Diseases

1
2
3
R

Name

Wayrilz

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Sickle cell disease

Sickle cell disease

Therapeutic Area

Rare Diseases

1
2
3
R

Name

Wayrilz

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Warm autoimmune hemolytic anemia

Warm autoimmune hemolytic anemia

Therapeutic Area

Rare Diseases

1
2
3
R

Name

venglustat

Phase

1
2
3
R

Description

Oral GCS inhibitor
New phase

Indication

Gaucher disease type 3 (US, EU, JP)

New phase

Gaucher disease type 3 (US, EU, JP)

New phase

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0269

Phase

1
2
3
R

Description

mRNA vaccine

Indication

Chlamydia

Chlamydia

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0287

Phase

1
2
3
R

Description

Flublok+Nuvaxovid

Indication

Influenza+COVID-19

Influenza+COVID-19

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0287

Phase

1
2
3
R

Description

Fluzone HD+Nuvaxovid

Indication

Influenza+COVID-19

Influenza+COVID-19

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0291

Phase

1
2
3
R

Description

mRNA vaccine

Indication

RSV+hMPV+PIV3 (older adults)

RSV+hMPV+PIV3 (older adults)

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0340

Phase

1
2
3
R

Description

Subunit vaccine

Indication

RSV+hMPV (older adults)

RSV+hMPV (older adults)

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0341

Phase

1
2
3
R

Description

Subunit vaccine

Indication

RSV+hMPV+PIV3 (older adults)

RSV+hMPV+PIV3 (older adults)

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0342

Phase

1
2
3
R

Description

Subunit adjuvanted vaccine

Indication

Shingles

Shingles

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0256

Phase

1
2
3
R

Description

mRNA vaccine

Indication

RSV+hMPV (older adults)

RSV+hMPV (older adults)

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0268

Phase

1
2
3
R

Description

mRNA vaccine

Indication

Acne

Acne

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0289

Phase

1
2
3
R

Description

mRNA vaccine

Indication

Influenza H5 pandemic

Influenza H5 pandemic

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0335

Phase

1
2
3
R

Description

Inactivated adjuvanted vaccine

Indication

Influenza H5 pandemic

Influenza H5 pandemic

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0202

Phase

1
2
3
R

Description

21-valent conjugate vaccine

Indication

Pneumococcal disease (children)

Pneumococcal disease (children)

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0218

Phase

1
2
3
R

Description

Vero cell vaccine

Indication

Yellow fever

Yellow fever

Therapeutic Area

Vaccines

1
2
3
R

Name

Fluzone HD

Phase

1
2
3
R

Description

Multivalent inactivated vaccine

Indication

Influenza (50 years+) (US, EU)

Influenza (50 years+) (US, EU)

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0087

Phase

1
2
3
R

Description

Vero cell vaccine
New phase

Indication

Rabies (EU)

New phase

Rabies (EU)

New phase

Related Links

Shuang Yang, with dark tied up hair and safety glasses, as seen through some equipment in a lab, with only her head visible

Research & Development

See more
An overhead view of a technician weighing a large plastic container of white powder, with hundreds of smaller containers nearby

Technology Platforms

See more
Overhead view of a desk with a healthcare professional and a patient in conversation, stethoscope and laptop visible.

Clinical Trials & Results

See more